Literature DB >> 21912938

Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells.

Junyu Wang1, Qi Wang, Yong Cui, Zhen Yang Liu, Wei Zhao, Chun Lin Wang, Yan Dong, Lijun Hou, Guohan Hu, Chun Luo, Juxiang Chen, Yicheng Lu.   

Abstract

Elevated cyclin D1 (CCND1) in human glioblastoma correlates with poor clinical prognosis. In this study, the human glioblastoma cell lines SHG-44 and U251 were stably transfected with short hairpin RNA (shRNA) targeting cyclin D1 or with ectogenic cyclin D1 by lentivirus-mediated transfection. Glioblastoma cells overexpressing or underexpressing cyclin D1 were then examined by in vitro growth assays, apoptosis assays, cell cycle analysis, and invasion assays. Cyclin D1 knockdown in SHG-44 cells inhibited cell proliferation, induced apoptosis, and attenuated migration across Matrigel, a model of invasive capacity. Western blot analysis and quantitative reverse-transcription polymerase chain reaction (RT-PCR) revealed that cells underexpressing CCND1 exhibited decreased multidrug resistance protein 1 (MDR1) and B-cell lymphoma-2 (Bcl-2) expression, but enhanced apoptosis effector caspase-3 expression. In contrast, cyclin D1 overexpression promoted cell proliferation, attenuated apoptosis, and enhanced invasive capacity. Furthermore, cyclin D1 overexpression was associated with increased expression of MDR1 and Bcl-2, and decreased caspase-3 expression. Results using the U251 cell line confirmed the effects of CCND1-targeted shRNA and lentivirus-mediated overexpression on proliferation and apoptosis of glioblastoma cells. Overexpression of cyclin D1 enhanced the proliferation and invasive potential of human glioblastoma cells, while reducing apoptosis. The ability to suppress the malignant phenotype by downregulating cyclin D1 expression may provide a new gene therapy approach for patients with malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21912938     DOI: 10.1007/s11060-011-0692-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  45 in total

Review 1.  CDK-independent activities of D type cyclins.

Authors:  R Bernards
Journal:  Biochim Biophys Acta       Date:  1999-10-29

Review 2.  Neuro-oncology: the growing role of chemotherapy in glioma.

Authors:  Antoine F Carpentier
Journal:  Lancet Neurol       Date:  2005-01       Impact factor: 44.182

3.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

4.  Cyclin D1 in astrocytic tumours: an immunohistochemical study.

Authors:  A Chakrabarty; L R Bridges; S Gray
Journal:  Neuropathol Appl Neurobiol       Date:  1996-08       Impact factor: 8.090

5.  MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors.

Authors:  K Tóth; M M Vaughan; N S Peress; H K Slocum; Y M Rustum
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

6.  Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.

Authors:  E R Sauter; M Nesbit; S Litwin; A J Klein-Szanto; S Cheffetz; M Herlyn
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

7.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; T Komeda; R Kita; T Sando; M Furukawa; M Amenomori; I Shibagaki; K Nakao; M Ikenaga
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

Review 8.  Cyclin D1, EMS1 and 11q13 amplification in breast cancer.

Authors:  Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland
Journal:  Breast Cancer Res Treat       Date:  2003-04       Impact factor: 4.872

9.  Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells.

Authors:  P Zhou; W Jiang; Y J Zhang; S M Kahn; I Schieren; R M Santella; I B Weinstein
Journal:  Oncogene       Date:  1995-08-03       Impact factor: 9.867

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  38 in total

Review 1.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

2.  The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Authors:  Lauren E Bartels; George Mattheolabakis; Brandon M Vaeth; Joseph F LaComb; Ruixue Wang; Jizu Zhi; Despina Komninou; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2016-02-10       Impact factor: 4.944

3.  t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65.

Authors:  Junyang Li; Hongyi Liu; Biao Xing; Yanzhe Yu; Hui Wang; Gong Chen; Bing Gu; Guofeng Zhang; Dong Wei; Peiyuan Gu; Meng Li; Weixing Hu
Journal:  J Neurooncol       Date:  2012-03-02       Impact factor: 4.130

4.  Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.

Authors:  Jilian R Melamed; Stephen A Ioele; Ariel J Hannum; Violet M Ullman; Emily S Day
Journal:  Mol Pharm       Date:  2018-10-11       Impact factor: 4.939

5.  Resetting cancer stem cell regulatory nodes upon MYC inhibition.

Authors:  Silvia Galardi; Mauro Savino; Fiorella Scagnoli; Serena Pellegatta; Federica Pisati; Federico Zambelli; Barbara Illi; Daniela Annibali; Sara Beji; Elisa Orecchini; Maria Adele Alberelli; Clara Apicella; Rosaria Anna Fontanella; Alessandro Michienzi; Gaetano Finocchiaro; Maria Giulia Farace; Giulio Pavesi; Silvia Anna Ciafrè; Sergio Nasi
Journal:  EMBO Rep       Date:  2016-11-16       Impact factor: 8.807

6.  Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer.

Authors:  Hui Gao; Yongji Liu; Kan Li; Tianhui Wu; Jianjun Peng; Fanbo Jing
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.

Authors:  Qi Wang; Jun Qian; Junyu Wang; Chun Luo; Juxiang Chen; Guohan Hu; Yicheng Lu
Journal:  J Neurooncol       Date:  2013-01-06       Impact factor: 4.130

8.  Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.

Authors:  Emma Camacho-Urkaray; Jorge Santos-Juanes; Francisco Borja Gutiérrez-Corres; Beatriz García; Luis M Quirós; Isabel Guerra-Merino; José Javier Aguirre; Iván Fernández-Vega
Journal:  Cell Oncol (Dordr)       Date:  2017-12-07       Impact factor: 6.730

Review 9.  Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.

Authors:  Neha Vartak-Sharma; Shruthi Nooka; Anuja Ghorpade
Journal:  Prog Neurobiol       Date:  2016-04-14       Impact factor: 11.685

10.  Characterization of fenofibrate-mediated anti-proliferative pro-apoptotic effects on high-grade gliomas and anti-invasive effects on glioma stem cells.

Authors:  Emanuela Binello; Elisabetta Mormone; Luni Emdad; Harini Kothari; Isabelle M Germano
Journal:  J Neurooncol       Date:  2014-02-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.